Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium

Pål Møller(Norwegian Cancer Society), Toni T. Seppälä(University of Helsinki), James G. Dowty(The University of Melbourne), Saskia Haupt(Heidelberg University), Mev Dominguez–Valentin(Norwegian Cancer Society), Lone Sunde(Aarhus University), Inge Bernstein(Aalborg University Hospital), Christoph Engel(Leipzig University), Stefan Aretz(University of Bonn), Maartje Nielsen(Leiden University Medical Center), Gabriel Capellá(Institut d'Investigació Biomédica de Bellvitge), D. Gareth Evans(Manchester University NHS Foundation Trust), John Burn(Newcastle University), Elke Holinski‐Feder(LMU Klinikum), Lucio Bertario(European Institute of Oncology), Bernardo Bonanni(European Institute of Oncology), Annika Lindblom(Karolinska Institutet), Zohar Levi(Rabin Medical Center), Finlay Macrae(The Royal Melbourne Hospital), Ingrid Winship(The Royal Melbourne Hospital), John‐Paul Plazzer(The Royal Melbourne Hospital), Rolf H. Sijmons(University Medical Center Groningen), Luigi Laghi(University of Parma), Adriana Della Valle(Hospital Central de las Fuerzas Armadas), Karl Heinimann(University Hospital of Basel), Elizabeth Half(Rambam Health Care Campus), Francisco Lopez-Koestner(Universidad de Los Andes, Chile), Karin Alvarez-Valenzuela(Universidad de Los Andes, Chile), Rodney J. Scott(Hunter Medical Research Institute), Lior H. Katz(Hebrew University of Jerusalem), Ido Laish(Sheba Medical Center), E Vainer(Hebrew University of Jerusalem), Carlos Vaccaro(Hospital Italiano de Buenos Aires), Dirce Maria Carraro(AC Camargo Hospital), Nathan Gluck(Tel Aviv University), Naim Abu‐Freha(Ben-Gurion University of the Negev), Áine Stakelum(St. Vincent's University Hospital), Rory Kennelly(St. Vincent's University Hospital), D. C. Winter(St. Vincent's University Hospital), Bernard Rossi(Hospital Sírio-Libanês), Marc S. Greenblatt(University of Vermont), Mábel Bohórquez(University of Tolima), Harsh Sheth(Institute of Genetics and Hospital for Genetic Diseases), Maria Grazia Tibiletti(University of Insubria), Leonardo S. Lino‐Silva(Instituto Nacional de Cancerología), Karoline Horisberger(University Hospital of Zurich), Carmen Portenkirchner(University Hospital of Zurich), Ivana do Nascimento, Norma Rossi(Hospital Privado), Leandro Apolinário da Silva(Hospital de Câncer de Pernambuco), Huw Thomas(St Mark's Hospital), Attila Zaránd(Semmelweis University), Jukka‐Pekka Mecklin(Central Finland Health Care District), Kirsi Pylvänäinen(Central Finland Health Care District), Laura Renkonen‐Sinisalo(University of Helsinki), Anna Lepistö(University of Helsinki), Païvi Peltomäki(University of Helsinki), Christina Therkildsen(Amager Hospital), Lars Joachim Lindberg(Amager Hospital), Ole Thorlacius‐Ussing(Aalborg University Hospital), Magnus von Knebel Doeberitz(German Cancer Research Center), Markus Loeffler(Leipzig University), Nils Rahner(Düsseldorf University Hospital), Verena Steinke‐Lange(LMU Klinikum), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Deepak Vangala(Universitätsklinikum Knappschaftskrankenhaus Bochum), Claudia Perne(University of Bonn), Robert Hüneburg(University Hospital Bonn), Aı́da Falcón de Vargas(Hospital Vargas), Andrew Latchford(St Mark's Hospital), Anne‐Marie Gerdes(Copenhagen University Hospital), A Bäckman(Karolinska Institutet), Carmen Guillén‐Ponce(Instituto Ramón y Cajal de Investigación Sanitaria), Carrie Snyder(Creighton University), Charlotte Kvist Lautrup(Aalborg University Hospital), David J. Amor(Royal Children's Hospital), Edenir Inêz Palmero(Hospital de Câncer de Barretos), Elena M. Stoffel(University of Michigan), Floor A.M. Duijkers(Amsterdam University Medical Centers), Michael J. Hall(Fox Chase Cancer Center), Heather Hampel(The Ohio State University), Heinric Williams(Geisinger Medical Center), Henrik Okkels(Aalborg University), Jan Lubiński(International Hereditary Cancer Center), Jeanette C. Reece(The University of Melbourne), Joanne Ngeow(Nanyang Technological University), José G. Guillem(University of North Carolina at Chapel Hill), Julie Arnold(Cancer Society of New Zealand), Karin Wadt(Copenhagen University Hospital), Kevin Monahan(St Mark's Hospital), Leigha Senter(The Ohio State University), Lene Juel Rasmussen(University of Copenhagen), Liselotte P. van Hest(Amsterdam University Medical Centers), Luigi Ricciardiello(University of Bologna), Maija R.J. Kohonen‐Corish(Woolcock Institute of Medical Research), Marjolijn J. L. Ligtenberg(Radboud University Nijmegen), Melissa C. Southey(Monash Health), Melyssa Aronson(Sinai Health System), Mohd Nizam Zahary(Sultan Zainal Abidin University), N. Jewel Samadder(WinnMed), Nicola Poplawski(Royal Adelaide Hospital), Nicoline Hoogerbrugge(Radboud University Nijmegen), Patrick J. Morrison(Queen's University Belfast), Paul A. James(The University of Melbourne), Grant Lee(The University of Melbourne), Rakefet Chen‐Shtoyerman(Kaplan Medical Center), Ravindran Ankathil(Universiti Sains Malaysia), Rish K. Pai(Mayo Clinic in Arizona), Robyn L. Ward(The University of Sydney), Susan Parry(Cancer Society of New Zealand), Tadeusz Dębniak(Pomeranian Medical University), Thomas John(Peter MacCallum Cancer Centre), Thomas van Overeem Hansen(Copenhagen University Hospital), Trinidad Caldés(Hospital Clínico San Carlos), Tatsuro Yamaguchi(Tokyo Metropolitan Komagome Hospital), Verónica Barca-Tierno(Instituto Ramón y Cajal de Investigación Sanitaria), Pilar Garré(Hospital Clínico San Carlos), Giulia Martina Cavestro(Vita-Salute San Raffaele University), Jürgen Weitz(Technische Universität Dresden), Silke Redler(Düsseldorf University Hospital), Reinhard Büttner(University Hospital Cologne), Vincent Heuveline(Heidelberg University), John L. Hopper(The University of Melbourne), Aung Ko Win(The University of Melbourne), Noralane M. Lindor(Mayo Clinic Hospital), Steven Gallinger(Mount Sinai Hospital), Loı̈c Le Marchand(University of Hawaiʻi at Mānoa), Polly A. Newcomb(Fred Hutch Cancer Center), Jane C. Figueiredo(Fred Hutch Cancer Center), Daniel D. Buchanan(The Royal Melbourne Hospital), Stephen N. Thibodeau(Mayo Clinic in Arizona), Sanne W. ten Broeke(Leiden University Medical Center), Eivind Hovig(University of Oslo), Sigve Nakken(University of Oslo), Marta Pineda(Institut d'Investigació Biomédica de Bellvitge), Núria Dueñas(Institut d'Investigació Biomédica de Bellvitge), Joan Brunet(Institut d'Investigació Biomédica de Bellvitge), Kate Green(Manchester University NHS Foundation Trust), Fiona Lalloo(Manchester University NHS Foundation Trust), Katie Newton(University of Manchester), Emma J. Crosbie(University of Manchester), Miriam Mints(Karolinska University Hospital), Douglas Tjandra(The Royal Melbourne Hospital), Florencia Neffa(Hospital Central de las Fuerzas Armadas), Patricia Esperón(Hospital Central de las Fuerzas Armadas), Revital Kariv(Tel Aviv University), Guy Rosner(Tel Aviv University), Walter Pavicic(Consejo Nacional de Investigaciones Científicas y Técnicas), Pablo Kalfayan(Hospital Italiano de Buenos Aires), Giovana Tardin Torrezan(AC Camargo Hospital), Thiago Bassaneze(Hospital Sírio-Libanês), Claudia Martin(Hospital de Câncer de Pernambuco), Gabriela Möslein(Witten/Herdecke University), Aysel Ahadova(Heidelberg University), Matthias Kloor(Heidelberg University), Julian R. Sampson(Cardiff University), Mark A. Jenkins(The University of Melbourne)
Hereditary Cancer in Clinical Practice
October 1, 2022
Cited by 56Open Access
Full Text

Abstract

OBJECTIVE: To compare colorectal cancer (CRC) incidences in carriers of pathogenic variants of the MMR genes in the PLSD and IMRC cohorts, of which only the former included mandatory colonoscopy surveillance for all participants. METHODS: CRC incidences were calculated in an intervention group comprising a cohort of confirmed carriers of pathogenic or likely pathogenic variants in mismatch repair genes (path_MMR) followed prospectively by the Prospective Lynch Syndrome Database (PLSD). All had colonoscopy surveillance, with polypectomy when polyps were identified. Comparison was made with a retrospective cohort reported by the International Mismatch Repair Consortium (IMRC). This comprised confirmed and inferred path_MMR carriers who were first- or second-degree relatives of Lynch syndrome probands. RESULTS: In the PLSD, 8,153 subjects had follow-up colonoscopy surveillance for a total of 67,604 years and 578 carriers had CRC diagnosed. Average cumulative incidences of CRC in path_MLH1 carriers at 70 years of age were 52% in males and 41% in females; for path_MSH2 50% and 39%; for path_MSH6 13% and 17% and for path_PMS2 11% and 8%. In contrast, in the IMRC cohort, corresponding cumulative incidences were 40% and 27%; 34% and 23%; 16% and 8% and 7% and 6%. Comparing just the European carriers in the two series gave similar findings. Numbers in the PLSD series did not allow comparisons of carriers from other continents separately. Cumulative incidences at 25 years were < 1% in all retrospective groups. CONCLUSIONS: Prospectively observed CRC incidences (PLSD) in path_MLH1 and path_MSH2 carriers undergoing colonoscopy surveillance and polypectomy were higher than in the retrospective (IMRC) series, and were not reduced in path_MSH6 carriers. These findings were the opposite to those expected. CRC point incidence before 50 years of age was reduced in path_PMS2 carriers subjected to colonoscopy, but not significantly so.


Related Papers

No related papers found

Powered by citation graph analysis